Pluristem Therapeutics Inc. news

   Watch this stock
Showing stories 1 - 10 of about 63   

Articles published

PSTI 2.93 0.00 (0.00%)
price chart
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4%
Pluristem Therapeutics, Inc. (PSTI - Snapshot Report) was a big mover last session, as the company saw its shares rise over 7% on the day.
Pluristem Therapeutics, Inc. (PSTI) in Focus: Stock Up 7.4% - Tale of the Tape
Pluristem Therapeutics, Inc. ( PSTI ) was a big mover last session, as the company saw its shares rise over 7% on the day.
Pluristem rebuffs patent challenge (PSTI)  Seeking Alpha (registration)
Pluristem Therapeutics Lifted to "Outperform" at Zacks (PSTI)  WKRB News
Related articles »  
Insider Buying: Pluristem Therapeutics COO Buys 11000 Shares of Stock (PSTI)
Pluristem Therapeutics Inc (NASDAQ:PSTI) is a bio-therapeutics company engaged in the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders.
Pluristem Therapeutics Earns Outperform Rating from Analysts at Oppenheimer ...  Mideast Time
Market Movers: National Bank of Greece (NYSE:NBG), Cisco Systems (NASDAQ ...  WallStreet Scope
Related articles »  
Zacks Upgrades Pluristem Therapeutics to "Outperform" (PSTI)
Pluristem Therapeutics Inc. logo Pluristem Therapeutics (NASDAQ:PSTI) was upgraded by Zacks from a �neutral� rating to an �outperform� rating in a note issued to investors on Monday.
Pluristem Therapeutics (PSTI) Releases Quarterly Earnings Results  Watch List News (press release)
Latest Developments: Pluristem Therapeutics Inc. (NASDAQ:PSTI), Vale SA ...  Market News Call
Related articles »  
United Therapeutics Points To Pluristem's PLX-PAD As Its Most Transformative ...
Among these, Pluristem Therapeutics, Inc. (NASDAQ:PSTI) offers the first and only cellular therapy for PAH, and recently made a significant move forward in clinical trials with its pharmaceutical partner, United Therapeutics Corp.
Coverage Initiation Report Focuses on Pluristem Therapeutics
NEW YORK, NY--(Marketwired - Oct 1, 2014) - Pluristem Therapeutics Inc. ( NASDAQ : PSTI) ( TASE : PLTR) is the subject of a new in-depth initiation coverage report by Acceleron Equity Research.
Related articles »  
Pluristem Therapeutics Coverage Initiated by Analysts at Oppenheimer (PSTI)
Pluristem Therapeutics Inc. logo Oppenheimer began coverage on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a research note released on Monday.
Oppenheimer Initiates Coverage on Pluristem Therapeutics (PSTI)  sleekmoney
Biotech Insider Buying : Halozyme Therapeutics (NASDAQ:HALO), RXi ...  WallStreet Scope
Related articles »  
Pluristem Therapeutics Rating Increased to Outperform at Zacks (PSTI)
Pluristem Therapeutics Inc. logo Zacks upgraded shares of Pluristem Therapeutics (NASDAQ:PSTI) from a neutral rating to an outperform rating in a research report sent to investors on Monday morning.
Market Highlight: Pluristem Therapeutics (PSTI), Christopher & Banks ...  USMarketsDaily (blog)
Stocks Alert- Pluristem Therapeutics Inc. (NASDAQ:PSTI), Tetraphase ...  Techsonian (press release)
Related articles »  
Pluristem Therapeutics Now Covered by Oppenheimer (PSTI)
Pluristem Therapeutics Inc. logo Investment analysts at Oppenheimer initiated coverage on shares of Pluristem Therapeutics (NASDAQ:PSTI) in a note issued to investors on Monday.
Related articles »  
Pluristem Therapeutics CEO Zami Aberman Purchases 15000 Shares (PSTI)
Pluristem Therapeutics logo Pluristem Therapeutics (NASDAQ:PSTI) CEO Zami Aberman acquired 15,000 shares of the company's stock on the open market in a transaction dated Tuesday, September 16th. The stock was purchased at an average price of ...
Pluristem Therapeutics Sees Strong Trading Volume on Insider Buying Activity ...  Watch List News (press release)
Stocks in news: Sunshine Heart (NASDAQ:SSH), Uranium Energy (NYSEMKT ...  WallStreet Scope
Related articles »